390 related articles for article (PubMed ID: 31053248)
21. Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms.
Kaemmerer D; Twrznik M; Kulkarni HR; Hörsch D; Sehner S; Baum RP; Hommann M;
Ann Surg; 2021 Jul; 274(1):e45-e53. PubMed ID: 33030849
[TBL] [Abstract][Full Text] [Related]
22. Treatment with
Estorch M
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):69-71. PubMed ID: 28257748
[No Abstract] [Full Text] [Related]
23. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms.
Ambrosini V; Kunikowska J; Baudin E; Bodei L; Bouvier C; Capdevila J; Cremonesi M; de Herder WW; Dromain C; Falconi M; Fani M; Fanti S; Hicks RJ; Kabasakal L; Kaltsas G; Lewington V; Minozzi S; Cinquini M; Öberg K; Oyen WJG; O'Toole D; Pavel M; Ruszniewski P; Scarpa A; Strosberg J; Sundin A; Taïeb D; Virgolini I; Wild D; Herrmann K; Yao J
Eur J Cancer; 2021 Mar; 146():56-73. PubMed ID: 33588146
[TBL] [Abstract][Full Text] [Related]
24. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
25. Molecular imaging Theranostics of Neuroendocrine Tumors.
Fortunati E; Bonazzi N; Zanoni L; Fanti S; Ambrosini V
Semin Nucl Med; 2023 Jul; 53(4):539-554. PubMed ID: 36623974
[TBL] [Abstract][Full Text] [Related]
26. Comparison of renal uptake of 68Ga-DOTANOC PET/CT and estimated glomerular filtration rate before and after peptide receptor radionuclide therapy in patients with metastatic neuroendocrine tumours.
Kaewput C; Vinjamuri S
Nucl Med Commun; 2016 Dec; 37(12):1325-1332. PubMed ID: 27612032
[TBL] [Abstract][Full Text] [Related]
27. Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors.
Ramage J; Naraev BG; Halfdanarson TR
Semin Oncol; 2018 Aug; 45(4):236-248. PubMed ID: 30539715
[No Abstract] [Full Text] [Related]
28. Pediatric applications of Dotatate: early diagnostic and therapeutic experience.
McElroy KM; Binkovitz LA; Trout AT; Czachowski MR; Seghers VJ; Lteif AN; States LJ
Pediatr Radiol; 2020 Jun; 50(7):882-897. PubMed ID: 32495176
[TBL] [Abstract][Full Text] [Related]
29. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
30. Polish experience in Peptide receptor radionuclide therapy.
Kunikowska J; Królicki L; Sowa-Staszczak A; Hubalewska-Dydejczyk A; Pawlak D; Mikolajczak R; Handkiewicz-Junak D; Szaluś N; Kamiński G; Cwikla J; Jakuciński M; Lukiewicz A; Kowalska A; Gut P
Recent Results Cancer Res; 2013; 194():467-78. PubMed ID: 22918776
[TBL] [Abstract][Full Text] [Related]
31. Overview of Development and Formulation of ¹⁷⁷Lu-DOTA-TATE for PRRT.
Breeman WA; Chan HS; de Zanger RM; Konijnenberg MK; de Blois E
Curr Radiopharm; 2016; 9(1):8-18. PubMed ID: 25771369
[TBL] [Abstract][Full Text] [Related]
32. Different technical possibilities of post-therapeutic tandem 90Y/ /177Lu-DOTATATE imaging.
Kunikowska J; Bajera A; Sawicka M; Czwarnowski P; Pawłowicz B; Aksamit D; Pawlak D; Królicki L
Nucl Med Rev Cent East Eur; 2013; 16(2):70-4. PubMed ID: 24068636
[TBL] [Abstract][Full Text] [Related]
33. Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors.
Taïeb D; Garrigue P; Bardiès M; Abdullah AE; Pacak K
PET Clin; 2015 Oct; 10(4):477-86. PubMed ID: 26384594
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
35. Quantitative SPECT/CT for Dosimetry of Peptide Receptor Radionuclide Therapy.
Kennedy J; Chicheportiche A; Keidar Z
Semin Nucl Med; 2022 Mar; 52(2):229-242. PubMed ID: 34911637
[TBL] [Abstract][Full Text] [Related]
36. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
[TBL] [Abstract][Full Text] [Related]
37. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC?
Öksüz MÖ; Winter L; Pfannenberg C; Reischl G; Müssig K; Bares R; Dittmann H
Diagn Interv Imaging; 2014 Mar; 95(3):289-300. PubMed ID: 24034971
[TBL] [Abstract][Full Text] [Related]
38. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
[TBL] [Abstract][Full Text] [Related]
39. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice.
Sheikhbahaei S; Sadaghiani MS; Rowe SP; Solnes LB
AJR Am J Roentgenol; 2021 Aug; 217(2):495-506. PubMed ID: 34076455
[No Abstract] [Full Text] [Related]
40. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
